BOXED O
WARNING O
: O
WARNING O
: O
HEPATOTOXICITY B-OSE_Labeled_AE
and O
RISK O
OF O
TERATOGENICITY O
WARNING O
: O
HEPATOTOXICITY O
and O
RISK O
OF O
TERATOGENICITY O
EXCERPT O
: O
WARNING O
: O
HEPATOTOXICITY O
and O
RISK O
OF O
TERATOGENICITY O
See O
full O
prescribing O
information O
for O
complete O
boxed O
warning O
Hepatotoxicity O
Severe O
liver O
injury O
including O
fatal O
liver O
failure O
has O
been O
reported O
in O
patients O
treated O
with O
leflunomide O
, O
which O
is O
indicated O
for O
rheumatoid O
arthritis O
. O

A O
similar O
risk O
would O
be O
expected O
for O
teriflunomide O
because O
recommended O
doses O
of O
teriflunomide O
and O
leflunomide O
result O
in O
a O
similar O
range O
of O
plasma O
concentrations O
of O
teriflunomide O
. O

Obtain O
transaminase O
and O
bilirubin O
levels O
within O
6 O
months O
before O
initiation O
of O
AUBAGIO O
and O
monitor O
ALT O
levels O
at O
least O
monthly O
for O
six O
months O
( O
5.1 O
) O
. O

If O
drug O
induced O
liver O
injury O
is O
suspected O
, O
discontinue O
AUBAGIO O
and O
start O
accelerated O
elimination O
procedure O
( O
5.3 O
) O
. O

Risk O
of O
Teratogenicity O
Based O
on O
animal O
data O
, O
AUBAGIO O
may O
cause O
major O
birth O
defects O
if O
used O
during O
pregnancy O
. O

AUBAGIO O
is O
contraindicated O
in O
pregnant O
women O
or O
women O
of O
childbearing O
potential O
who O
are O
not O
using O
reliable O
contraception O
. O

Pregnancy O
must O
be O
avoided O
during O
AUBAGIO O
treatment O
. O

( O
4.2 O
, O
5.2 O
) O
Hepatotoxicity O
Severe O
liver B-OSE_Labeled_AE
injury I-OSE_Labeled_AE
including O
fatal O
liver B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
has O
been O
reported O
in O
patients O
treated O
with O
leflunomide O
, O
which O
is O
indicated O
for O
rheumatoid B-Not_AE_Candidate
arthritis I-Not_AE_Candidate
. O

A O
similar O
risk O
would O
be O
expected O
for O
teriflunomide O
because O
recommended O
doses O
of O
teriflunomide O
and O
leflunomide O
result O
in O
a O
similar O
range O
of O
plasma O
concentrations O
of O
teriflunomide O
. O

Concomitant O
use O
of O
AUBAGIO O
with O
other O
potentially O
hepatotoxic B-NonOSE_AE
drugs O
may O
increase O
the O
risk O
of O
severe O
liver B-NonOSE_AE
injury I-NonOSE_AE
. O

Obtain O
transaminase O
and O
bilirubin O
levels O
within O
6 O
months O
before O
initiation O
of O
AUBAGIO O
therapy O
. O

Monitor O
ALT O
levels O
at O
least O
monthly O
for O
six O
months O
after O
starting O
AUBAGIO O
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
. O

If O
drug B-NonOSE_AE
induced I-NonOSE_AE
liver I-NonOSE_AE
injury I-NonOSE_AE
is O
suspected O
, O
discontinue O
AUBAGIO O
and O
start O
an O
accelerated O
elimination O
procedure O
with O
cholestyramine O
or O
charcoal O
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
. O

AUBAGIO O
is O
contraindicated O
in O
patients O
with O
severe O
hepatic B-Not_AE_Candidate
impairment I-Not_AE_Candidate
[ O
see O
Contraindications O
( O
4.1 O
) O
] O
. O

Patients O
with O
pre-existing O
liver B-Not_AE_Candidate
disease I-Not_AE_Candidate
may O
be O
at O
increased O
risk O
of O
developing O
elevated B-OSE_Labeled_AE
serum I-OSE_Labeled_AE
transaminases I-OSE_Labeled_AE
when O
taking O
AUBAGIO O
. O

Risk O
of O
Teratogenicity B-OSE_Labeled_AE
Based O
on O
animal O
data O
, O
AUBAGIO O
may B-OSE_Labeled_AE
cause I-OSE_Labeled_AE
major I-OSE_Labeled_AE
birth I-OSE_Labeled_AE
defects I-OSE_Labeled_AE
if O
used O
during O
pregnancy B-Not_AE_Candidate
. O

Pregnancy B-NonOSE_AE
must O
be O
excluded O
before O
starting O
AUBAGIO O
. O

AUBAGIO O
is O
contraindicated O
in O
pregnant B-Not_AE_Candidate
women I-Not_AE_Candidate
or O
women O
of O
childbearing O
potential O
who O
are O
not O
using O
reliable O
contraception O
. O

Pregnancy B-NonOSE_AE
must O
be O
avoided O
during O
AUBAGIO O
treatment O
or O
prior O
to O
the O
completion O
of O
an O
accelerated O
elimination O
procedure O
after O
AUBAGIO O
treatment O
[ O
see O
Contraindications O
( O
4.2 O
) O
, O
Warnings O
and O
Precautions O
( O
5.2 O
) O
, O
and O
Use O
in O
Specific O
Populations O
( O
8.1 O
) O
] O
. O

